This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ASCCP Releases Updated Consensus Guidelines For Managing Abnormal Cervical Cancer Screening Tests And Cancer Precursors

Guidelines Developed with 23 National Health Organizations and Nine Years of Cervical Precancer-Management Data on 1.4 million Women

FREDERICK, Md., March 21, 2013 /PRNewswire-USNewswire/ -- The American Society for Colposcopy and Cervical Pathology ( ASCCP) today released the Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors.

A group of 47 experts representing 23 professional societies, national and international health organizations, and federal agencies met in Bethesda, MD, September 14 -15, 2012, to update the ASCCP Consensus Guidelines published in 2007. The group's goal was to provide revised evidence-based consensus guidelines for managing women with abnormal cervical cancer screening tests, and diagnosed cancer precursors.  These guidelines follow adoption of updated cervical cancer screening guidelines in 2012 incorporating longer screening intervals and cotesting. In addition to literature review for specific issues, data from almost 1.4 million women in the Kaiser Permanente Northern California Medical Care Plan provided evidence on risk of cervical precancer and invasive cancer over an eight year period after abnormal tests and follow up.

The Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors are coauthored by L. Stewart Massad, MD, Mark H. Einstein, MD, Warner K. Huh, MD, Hormuzd A. Katki, PhD, Walter K. Kinney, MD, Mark Schiffman, MD, Diane Solomon, MD, Nicolas Wentzensen, MD, and Herschel W. Lawson, MD, for the 2012 ASCCP Consensus Guidelines Conference

The educational mission of the ASCCP is to improve clinician competence and performance and patient outcomes through educational activities focused on the study, prevention, diagnosis, and management of lower genital tract disorders. The ASCCP was founded in 1964 and is a 501(c)(3) organization.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GOOG $691.60 -0.11%
TSLA $232.35 0.01%
YHOO $35.92 -0.25%
AAPL $95.18 0.00%
FB $117.58 0.13%


Chart of I:DJI
DOW 17,671.67 -79.24 -0.45%
S&P 500 2,052.89 -10.48 -0.51%
NASDAQ 4,738.5050 -24.7190 -0.52%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs